Dataset Information

Cell-free DNA sequencing data of healthy control, atrophic gastritis, and gastric cancer patientsÃ¢Â€Â™ blood

ABSTRACT: In this study, cell-free DNA sequencing is performed to obtain a personalized genetic profile of cell-free DNA during the course of gastric cancer. The study involves control, premalignant (atrophic gastritis), and malignant gastric cancer cases. Detected variant alleles and determined fractions during the course of a disease, will show the possible application of cfDNA as a minimally-invasive biomarker for not only early GC diagnostics but also for GC disease state monitoring.

PROVIDER: EGAS00001007308 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Similar Datasets

Project description:Background: Gastric cancer (GC) remains the third leading cause of cancer death worldwide due to the absence of sensitive and specific biomarkers for its early detection. 5-hydroxymethylcytosine (5hmC)-enriched gene profiles and regions show tissue-specific and tumor specific, and cell-free DNA (cfDNA) 5hmC modification feature sequencing provides a robust tool for gastric cancer detection.Methods: A matched case‒control study design with 50 gastric cancer patients and 50 controls was performed to sequence the 5hmC modification of cfDNA. Significantly differential 5hmC modification genes were identified to construct a gastric cancer diagnostic model. The data set from Gene Expression Omnibus consisted of 61 gastric cancer patients, 90 healthy individuals and 22 benign gastric disease controls was used as an external testing set to test the robustness of the diagnostic model. Results: The vast majority of 5hmC peaks were distributed in the gene body, accounting for more than 90% of the total 5hmC peaks in both the GC and control groups. The diagnostic model was developed based on five different 5hmC modification genes, FBXL7, PDE3A, TPO, SNTG2 and SXBP5. The model could clearly distinguish gastric cancer patients from controls in the training (AUC=0.95, sensitivity=88.6%, specificity=94.3%), validation (AUC=0.87, sensitivity=73.3%, specificity=93.3%) and testing (AUC=0.90, sensitivity=81.9%, specificity=90.2%) sets. The predicted risk scores of the controls were significantly lower than those of GC patients in our own data (P<0.001) or GEO external testing data (P<0.001), but no significant difference was observed between different TNM stage groups (P=0.09 and 0.66). Furthermore, the risk scores of healthy and benign gastric disease controls in the testing set were also not different (P=0.10). Conclusions: The characteristics of 5hmC in cfDNA are specific to GC patients, and the diagnostic model constructed by the 5hmC features of five genes could effectively identify GC patients.

Dataset Information

Cell-free DNA sequencing data of healthy control, atrophic gastritis, and gastric cancer patientsÃ¢Â€Â™ blood

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets